Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt.
Animals
Benzothiazoles
/ pharmacology
Bone Neoplasms
/ enzymology
Breast Neoplasms
/ enzymology
Bridged-Ring Compounds
/ pharmacology
Cell Line, Tumor
Cell Movement
/ drug effects
Female
Humans
Lung Neoplasms
/ enzymology
Mice
Mice, Knockout
Neoplasm Invasiveness
/ genetics
Phosphatidylinositol 3-Kinases
/ metabolism
Phosphotransferases (Alcohol Group Acceptor)
/ antagonists & inhibitors
Proto-Oncogene Proteins c-akt
/ metabolism
RNA, Small Interfering
Up-Regulation
ceramide kinase
metastatic breast cancer cells
migration and invasion
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Feb 2020
19 Feb 2020
Historique:
received:
29
11
2019
revised:
28
01
2020
accepted:
12
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Ceramide kinase (CerK) is a lipid kinase that converts the proapoptotic ceramide to ceramide 1-phosphate, which has been proposed to have pro-malignant properties and regulate cell responses such as proliferation, migration, and inflammation. We used the parental human breast cancer cell line MDA-MB-231 and two single cell progenies derived from lung and bone metastasis upon injection of the parental cells into immuno-deficient mice. The lung and the bone metastatic cell lines showed a marked upregulation of CerK mRNA and activity when compared to the parental cell line. The metastatic cells also had increased migratory and invasive activity, which was dose-dependently reduced by the selective CerK inhibitor NVP-231. A similar reduction of migration was seen when CerK was stably downregulated with small hairpin RNA (shRNA). Conversely, overexpression of CerK in parental MDA-MB-231 cells enhanced migration, and this effect was also observed in the non-metastatic cell line MCF7 upon CerK overexpression. On the molecular level, CerK overexpression increased the activation of protein kinase Akt. The increased migration of CerK overexpressing cells was mitigated by the CerK inhibitor NVP-231, by inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway and the Rho kinase, but not by inhibition of the classical extracellular signal-regulated kinase (ERK) pathway. Altogether, our data demonstrate for the first time that CerK promotes migration and invasion of metastatic breast cancer cells and that targeting of CerK has potential to counteract metastasis in breast cancer.
Identifiants
pubmed: 32092937
pii: ijms21041396
doi: 10.3390/ijms21041396
pmc: PMC7073039
pii:
doi:
Substances chimiques
Benzothiazoles
0
Bridged-Ring Compounds
0
NVP 231
0
RNA, Small Interfering
0
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
ceramide kinase
EC 2.7.1.138
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_153346/1
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1039
Références
J Biol Chem. 2004 Apr 23;279(17):17570-7
pubmed: 14769792
Biochem Pharmacol. 2016 Feb 15;102:107-119
pubmed: 26707801
Ann Ist Super Sanita. 2015;51(2):139-47
pubmed: 26156185
Cell Physiol Biochem. 2014;34(1):119-33
pubmed: 24977486
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1215-9
pubmed: 15504344
Pharmacol Ther. 2017 Apr;172:101-115
pubmed: 27919797
J Cancer Res Clin Oncol. 2009 Aug;135(8):1005-13
pubmed: 19125296
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
J Biol Chem. 2002 Jun 28;277(26):23294-300
pubmed: 11956206
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569627
Mol Cancer Res. 2010 May;8(5):629-42
pubmed: 20460404
J Lipid Res. 2014 Jul;55(7):1298-309
pubmed: 24823941
Am J Transl Res. 2019 Sep 15;11(9):5301-5312
pubmed: 31632511
Stem Cells. 2013 Mar;31(3):500-10
pubmed: 23193025
J Lipid Res. 2007 Jun;48(6):1293-304
pubmed: 17392267
Nature. 2014 Oct 16;514(7522):309-10
pubmed: 25318518
J Biol Chem. 2008 Mar 28;283(13):8517-26
pubmed: 18086664
Biochim Biophys Acta. 2016 Nov;1861(11):1840-1851
pubmed: 27616330
Biochem Biophys Res Commun. 2006 Apr 7;342(2):611-7
pubmed: 16488390
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
J Proteome Res. 2010 Jan;9(1):420-9
pubmed: 19899769
Autophagy. 2018;14(5):862-879
pubmed: 29164996
Mol Cell Biol. 2004 May;24(9):3804-14
pubmed: 15082775
Placenta. 1998 Nov;19(8):587-93
pubmed: 9859862
Br J Pharmacol. 2014 Dec;171(24):5829-44
pubmed: 25134723
Oncotarget. 2016 Apr 12;7(15):20919-33
pubmed: 26989024
Biochim Biophys Acta. 2009 Oct;1791(10):1023-30
pubmed: 19501188
Exp Cell Res. 2015 May 1;333(2):195-200
pubmed: 25770011
Cell Signal. 2009 Mar;21(3):405-12
pubmed: 19041940
Crit Rev Oncol Hematol. 2007 Aug;63(2):150-9
pubmed: 17560117
J Biol Chem. 2003 Oct 3;278(40):38206-13
pubmed: 12855693
FEBS J. 2008 Aug;275(15):3815-26
pubmed: 18565104
Cell Signal. 2019 Feb;54:59-68
pubmed: 30448345
Biomed Res Int. 2015;2015:165105
pubmed: 25866760
Biochem Biophys Res Commun. 2011 Jun 10;409(3):506-12
pubmed: 21600875
Mediators Inflamm. 2017;2017:4806541
pubmed: 29269995
Cell Signal. 2011 Jun;23(6):999-1008
pubmed: 21111813
Cancer Res. 2014 Nov 1;74(21):6352-63
pubmed: 25164007
Nat Rev Cancer. 2010 Jul;10(7):489-503
pubmed: 20555359
Curr Opin Cell Biol. 2017 Apr;45:62-71
pubmed: 28343126
J Biol Chem. 1989 Aug 25;264(24):14354-60
pubmed: 2547795
J Biol Chem. 2007 Jul 13;282(28):20467-74
pubmed: 17472963
Biochim Biophys Acta. 2016 May;1861(5):402-9
pubmed: 26875839
Microvasc Res. 2009 May;77(3):389-93
pubmed: 19323974
Mol Pharmacol. 2008 Oct;74(4):925-32
pubmed: 18612076
J Biol Chem. 1998 Dec 11;273(50):33203-9
pubmed: 9837889
Curr Pharm Des. 2006;12(35):4625-35
pubmed: 17168766
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087